ArticleInternational journal of biomedical imaging2026
REFA-DINO: A Relative-Efficient Fusion Attention Framework for Binary and Multiclass Diabetic Retinopathy Classification.
Article in International journal of biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- REFA-DINO: A Relative-Efficient Fusion Attention Framework for Binary and Multiclass Diabetic Retinopathy Classification.International journal of biomedical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) has become a major cause of preventable blindness, and its early detection is crucial for maintaining vision in diabetic patients. Existing computer-aided diagnosis (CAD) systems still face challenges in detecting early-stage lesions, integrating local and global features, and maintaining consistent performance in binary and multiclass settings. To address these limitations, this study proposes a relative-efficient fusion attention framework (REFA-DINO) that integrates a convolutional local-feature learning module with a transformer-based global contextual method. The architecture employs a relative-efficient fusion adapter (REFA) block comprising two branches, EfficientNet and attention-enhanced patch embedding. EfficientNet extracts lesion-sensitive retinal features, and an attention-enhanced patch-embedding module is used to generate token representations. An adaptive relative position-aware cross-attention mechanism is introduced to enable effective interaction among heterogeneous features, which are further processed through the DINO-based transformer module. The extracted global representations are passed to the linear classification head for DR classification. REFA-DINO is evaluated on two diverse and large-scale fundus imaging datasets, EyePACS and APTOS, for binary and multiclass classification. The proposed framework achieved accuracies of 98.60% and 93.77% for binary classification and 85.52% and 87.51% for multiclass classification on the APTOS and EyePACS datasets, respectively. A comparative analysis against state-of-the-art methods, cross-corpora evaluation, and an ablation study are also conducted to demonstrate the effectiveness of the proposed REFA-DINO. Compared with state-of-the-art methods, the REFA-DINO framework enhances binary classification on both the EyePACS and APTOS datasets, with significant improvements over the strongest baselines. The proposed approach attains up to 6.19% and 9.39% improvement in the binary and multiclass classification accuracy on EyePACS. Likewise, it achieves an improvement of 2.64% on the binary classification score on APTOS with competitive multiclass classification performance. Experimental findings highlight the robustness and generalizability of the REFA-DINO framework in classifying DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.